New antimicrobial cystatin C-based peptide active against gram-positive bacterial pathogens, including methicillin-resistant Staphylococcus aureus and multiresistant coagulase-negative staphylococci

APMIS

Volumn 111, Issue 11, 2003, Pages 1004-1010

  Jasir, Aftab ^a   Kasprzykowski, Franciszek ^b   Kasprzykowska, Regina ^b   Lindström, Veronica ^a   Schalen, Claes ^a   Grubb, Anders ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GDA SK   (Poland)

Author keywords

Antimicrobial peptide; Cystatin C; Gram positive pathogens; Staphylococcus aureus; Streptococcus pyogenes

Indexed keywords

2 (NALPHA BENZYLOXYCARBONYLARGINYLLEUCYLAMIDO) 1 (CINNAMOYLAMIDO) 3 METHYLBUTANE; ANTIINFECTIVE AGENT; CYSTAPEP 1; CYSTATIN C; CYSTEINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; GRAM POSITIVE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SYNTHESIS;

EID: 0346244038     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2003.t01-1-apm1111110.x     Document Type: Article

References (26)

1. Panlilio AL, Culver DH, Gaynes RP, et al. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992;13:582-6.
2. Morris JG Jr, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin. Establishment of endemicity in a university medical center. Ann Intern Med 1995;123:250-9.
3. Appelbaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992;15:77-83.
4. Seppälä H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997;337:441-6.
5. Steiner H, Hultmark D, Engstrom A, Bennich H, Boman HG. Sequence and specificity of two antibacterial proteins involved in insect immunity. Nature 1981;292:246-8.
6. Boman HG. Man's own antibiotics - an innate immune system. Nord Med 1996;111:176-9.
7. Hwang PM, Vogel HJ. Structure-function relationships of antimicrobial peptides. Biochem Cell Biol 1998;76:235-46.
8. Sahl HG, Bierbaum G. Lantibiotics: biosynthesis and biological activities of uniquely modified peptides from gram-positive bacteria. Annu Rev Microbiol 1998;52:41-79.
9. Andreu D, Ubach J, Boman A, et al. Shortened cecropin A-melittin hybrids. Significant size reduction retains potent antibiotic activity. FEBS Lett 1992;296:190-4.
10. Agerberth B, Boman A, Andersson M, Jornvall H, Mutt V, Boman HG. Isolation of three antibacterial peptides from pig intestine: gastric inhibitory polypeptide (7-42), diazepam-binding inhibitor (32-86) and a novel factor, peptide 3910. Eur J Biochem 1993;216:623-9.
11. Boman HG, Nilsson I, Rasmuson B. Inducible antibacterial defence system in Drosophila. Nature 1972;237:232-5.
12. Demel RA, Peelen T, Siezen RJ, De Kruijff B, Kuipers OP. Nisin Z, mutant nisin Z and lacticin 481 interactions with anionic lipids correlate with antimicrobial activity. A monolayer study. Eur J Biochem 1996;235:267-74.
13. Breukink E, van Kraaij C, Demel RA, Siezen RJ, Kuipers OP, de Kruijff B. The C-terminal region of nisin is responsible for the initial interaction of nisin with the target membrane. Biochemistry 1997;36:6968-76.
14. Kordel M, Schuller F, Sahl HG. Interaction of the pore forming-peptide antibiotics Pep 5, nisin and subtilin with non-energized liposomes. FEBS Lett 1989;244:99-102.
15. Björck L, Åkesson P, Bohus M, et al. Bacterial growth blocked by a synthetic peptide based on the structure of a human proteinase inhibitor. Nature 1989;337:385-6.
16. Rawlings ND, Barrett AJ. Evolution of proteins of the cystatin superfamily. J Mol Evol 1990; 30:60-71.
17. Blankenvoorde MF, Henskens YM, van't Hof W, Veerman EC, Nieuw Amerongen AV. Inhibition of the growth and cysteine proteinase activity of Porphyromonas gingivalis by human salivary cystatin S and chicken cystatin. Biol Chem 1996; 377:847-50.
18. Collins AR, Grubb A. Inhibitory effects of recombinant human cystatin C on human coronaviruses. Antimicrob Agents Chemother 1991; 35:2444-6.
19. Kondo H, Ijiri S, Abe K, Maeda H, Arai S. Inhibitory effect of oryzacystatins and a truncation mutant on the replication of poliovirus in infected Vero cells. FEBS Lett 1992;299:48-50.
20. Korant BD, Brzin J, Turk V. Cystatin, a protein inhibitor of cysteine proteases alters viral protein cleavages in infected human cells. Biochem Biophys Res Commun 1985;127:1072-6.
21. Naito Y, Sasaki M, Umemoto T, et al. Bactericidal effect of rat cystatin S on an oral bacterium Porphyromonas gingivalis. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1995;110: 71-5.
22. Takahashi M, Tezuka T, Katunuma N. Inhibition of growth and cysteine proteinase activity of Staphylococcus aureus V8 by phosphorylated cystatin alpha in skin cornified envelope. FEBS Lett 1994;355:275-8.
23. Abrahamson M, Ritonja A, Brown MA, Grubb A, Machleidt W, Barrett AJ. Identification of the probable inhibitory reactive sites of the cysteine proteinase inhibitors human cystatin C and chicken cystatin. J Biol Chem 1987;262:9688-94.
24. Bode W, Engh R, Musil D, et al. The 2.0 A X-ray crystal structure of chicken egg white cystatin and its possible mode of interaction with cysteine proteinases. Embo J 1988;7:2593-9.
25. Kasprzykowski F, Schalén C, Kasprzykowska R, Jastrzebska B, Grubb A. Synthesis and antibacterial properties of peptidyl derivatives and cyclopeptides structurally based upon the inhibitory centre of human cystatin C. Dissociation of antiproteolytic and antibacterial effects. APMIS 2000;108:473-81.
26. Orrling A, Stjernquist-Desatnik A, Schalén C, Kamme C. Treatment failure in streptococcal pharyngotonsillitis. An attempt to identify penicillin tolerant Streptococcus pyogenes. Scand J Infect Dis 1996;28:143-7.